Targeted conjugates and particles and formulations thereof
Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
1. A conjugate or a pharmaceutically acceptable salt thereof, comprising an active agent coupled to a somatostatin receptor (SSTR) targeting moiety by a linker,
wherein the active agent is mertansine (DM1),
wherein the SSTR targeting moiety is a peptide,
wherein the linker binds to the C-terminus of the peptide with a covalent bond,
wherein the molecular weight of the conjugate is less than 5000 Da, and
wherein the conjugate comprises a formula of
wherein
R is selected from the group consisting of H, alkyl, aryl, and amide groups; and
Ar 1 and Ar 2 are independently selected from the group consisting of heterocyclyl, aryl, and heteroaryl groups.
2. The conjugate of claim 1 , wherein the bond between the linker and the SSTR targeting moiety is an amide bond.
3. The conjugate of claim 1 , wherein the linker is a cleavable linker.
4. The conjugate of claim 1 , wherein the linker comprises an ester bond, disulfide, amide, acylhydrazone, ether, carbamate, carbonate, or urea.
5. A pharmaceutical formulation comprising the conjugate in claim 1 and at least one pharmaceutically acceptable excipient.
6. A conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate is selected from the group consisting of Compound 35, Compound 37, Compound 39, Compound 41, Compound 43, Compound 45, Compound 47, Compound 49, Compound 51, Compound 55, Compound 57, Compound 59, Compound 61, Compound 63, and Compound 65.
7. The conjugate of claim 6 , wherein the conjugate is
8. A pharmaceutical formulation comprising the conjugate in claim 6 and at least one pharmaceutically acceptable excipient.